memantine has been researched along with Schizophrenia in 45 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)." | 9.41 | Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023) |
| "Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia." | 9.34 | Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020) |
| "This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia." | 9.24 | The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017) |
| "In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 9.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
| "In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 9.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
| "We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 9.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
| "Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients." | 9.14 | Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009) |
| "Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits." | 9.13 | Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
| "Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients." | 9.01 | Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019) |
| "This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia." | 8.98 | Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018) |
| "We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics." | 7.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
| "We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy." | 7.80 | Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014) |
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 7.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| "Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 6.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
| "To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)." | 5.41 | Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023) |
| "Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia." | 5.34 | Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020) |
| "This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia." | 5.24 | The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017) |
| "In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 5.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
| "In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 5.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
| "We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 5.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
| "Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients." | 5.14 | Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009) |
| "Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits." | 5.13 | Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
| "Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients." | 5.01 | Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019) |
| "Fifteen RCTs (n = 988) examining memantine (5-20 mg/day) as an adjunct treatment for schizophrenia (9 trials with 512 patients), bipolar disorder (3 trials with 319 patients), and MDD (3 trials with 157 patients) were analyzed." | 5.01 | Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. ( Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019) |
| "This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia." | 4.98 | Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018) |
| "We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics." | 3.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 3.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| "We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy." | 3.80 | Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014) |
| "Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 2.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
| "Schizophrenia is a devastating psychiatric illness." | 2.41 | Imaging the glutamatergic system in vivo--relevance to schizophrenia. ( Bressan, RA; Pilowsky, LS, 2000) |
| "Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population." | 1.37 | Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (22.22) | 29.6817 |
| 2010's | 27 (60.00) | 24.3611 |
| 2020's | 8 (17.78) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, TC | 2 |
| Correll, CU | 2 |
| Yang, FC | 2 |
| Chen, MH | 2 |
| Tseng, PT | 2 |
| Hsu, CW | 2 |
| Carvalho, AF | 2 |
| Stubbs, B | 2 |
| Thompson, T | 2 |
| Chu, CS | 2 |
| Yu, CL | 2 |
| Il Shin, J | 2 |
| Yang, SN | 2 |
| Tu, YK | 2 |
| Liang, CS | 2 |
| Schaefer, M | 2 |
| Sarkar, S | 1 |
| Theophil, I | 1 |
| Leopold, K | 2 |
| Heinz, A | 2 |
| Gallinat, J | 1 |
| Martin, ED | 1 |
| Deardorff, OG | 1 |
| Menditto, AA | 1 |
| Sethi, S | 1 |
| Hopkins, TM | 1 |
| Li, H | 1 |
| Xing, M | 1 |
| Zhang, C | 1 |
| Molina, JL | 2 |
| Voytek, B | 1 |
| Thomas, ML | 2 |
| Joshi, YB | 3 |
| Bhakta, SG | 3 |
| Talledo, JA | 3 |
| Swerdlow, NR | 6 |
| Light, GA | 5 |
| Vayısoğlu, S | 1 |
| Karahan, S | 1 |
| Anıl Yağcıoğlu, AE | 1 |
| Kikuchi, T | 1 |
| Talledo, J | 1 |
| Kotz, J | 1 |
| Roberts, BZ | 1 |
| Clifford, RE | 1 |
| Czarnecka, K | 1 |
| Chuchmacz, J | 1 |
| Wójtowicz, P | 1 |
| Szymański, P | 1 |
| Zhang, W | 1 |
| Bhakta, S | 2 |
| Kishi, T | 3 |
| Matsuda, Y | 3 |
| Iwata, N | 3 |
| Zheng, W | 2 |
| Li, XH | 1 |
| Yang, XH | 2 |
| Cai, DB | 2 |
| Ungvari, GS | 2 |
| Ng, CH | 2 |
| Wang, SB | 1 |
| Wang, YY | 1 |
| Ning, YP | 2 |
| Xiang, YT | 2 |
| Omranifard, V | 1 |
| Rajabi, F | 1 |
| Mohammadian-Sichani, M | 1 |
| Maracy, MR | 1 |
| Koola, MM | 2 |
| Sklar, J | 1 |
| Davis, W | 1 |
| Nikiforuk, A | 1 |
| Meissen, JK | 1 |
| Sawant-Basak, A | 1 |
| Aaronson, ST | 2 |
| Kozak, R | 1 |
| Ikuta, T | 1 |
| Veerman, S | 1 |
| Schulte, P | 1 |
| de Haan, L | 4 |
| Kantrowitz, JT | 1 |
| Dunn, W | 1 |
| Vinogradov, S | 1 |
| Sekar, S | 1 |
| Grandjean, J | 1 |
| Garnell, JF | 1 |
| Willems, R | 1 |
| Duytschaever, H | 1 |
| Seramani, S | 1 |
| Su, H | 1 |
| Ver Donck, L | 1 |
| Bhakoo, KK | 1 |
| Uribe, E | 1 |
| Fernández, L | 2 |
| Pacheco, D | 1 |
| Nayadoleni, N | 1 |
| Eblen-Zajjur, A | 1 |
| Zhu, XM | 1 |
| Zhang, QE | 1 |
| Zhou, YL | 1 |
| He, SH | 1 |
| Peng, XJ | 1 |
| Rezaei, F | 1 |
| Mohammad-Karimi, M | 1 |
| Seddighi, S | 1 |
| Modabbernia, A | 1 |
| Ashrafi, M | 1 |
| Salehi, B | 1 |
| Hammidi, S | 1 |
| Motasami, H | 1 |
| Hajiaghaee, R | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Ene-Stroescu, V | 1 |
| Nguyen, T | 1 |
| Waiblinger, BE | 1 |
| Buchanan, RW | 1 |
| Pillai, A | 1 |
| Aitchison, KJ | 1 |
| Weinberger, DR | 1 |
| Dickerson, FB | 1 |
| Veerman, SR | 3 |
| Schulte, PF | 3 |
| Iasevoli, F | 1 |
| Buonaguro, EF | 1 |
| Sarappa, C | 1 |
| Marmo, F | 1 |
| Latte, G | 1 |
| Rossi, R | 1 |
| Eramo, A | 1 |
| Tomasetti, C | 1 |
| de Bartolomeis, A | 1 |
| John, JP | 1 |
| Lukose, A | 1 |
| Manjunath, S | 1 |
| Chou, HH | 1 |
| Balvaneda, B | 1 |
| Smith, JD | 1 |
| Deijen, JB | 1 |
| Mazinani, R | 1 |
| Nejati, S | 1 |
| Khodaei, M | 1 |
| Fakhri, A | 1 |
| Pakseresht, S | 1 |
| Haghdoost, MR | 1 |
| Hekmatkhah, N | 1 |
| Torkashvand, M | 1 |
| Ghorbanzadeh, B | 1 |
| Lieberman, JA | 1 |
| Papadakis, K | 1 |
| Csernansky, J | 1 |
| Litman, R | 1 |
| Volavka, J | 1 |
| Jia, XD | 1 |
| Gage, A | 1 |
| de Lucena, D | 2 |
| Fernandes, BS | 2 |
| Berk, M | 1 |
| Dodd, S | 1 |
| Medeiros, DW | 1 |
| Pedrini, M | 1 |
| Kunz, M | 2 |
| Gomes, FA | 1 |
| Giglio, LF | 1 |
| Lobato, MI | 1 |
| Belmonte-de-Abreu, PS | 2 |
| Gama, CS | 3 |
| Fries, GR | 1 |
| Stertz, L | 1 |
| Aguiar, B | 1 |
| Pfaffenseller, B | 1 |
| Dedeurwaerdere, S | 1 |
| Wintmolders, C | 1 |
| Straetemans, R | 1 |
| Pemberton, D | 1 |
| Langlois, X | 1 |
| Kato, T | 1 |
| Rands, GS | 1 |
| Antunes, P | 1 |
| Moser, C | 1 |
| Hinzpeter, A | 1 |
| Krebs, M | 1 |
| Krivoy, A | 1 |
| Weizman, A | 1 |
| Laor, L | 1 |
| Hellinger, N | 1 |
| Zemishlany, Z | 1 |
| Fischel, T | 1 |
| Cerullo, MA | 1 |
| Adler, CM | 1 |
| Strakowski, SM | 1 |
| Eliassen, JC | 1 |
| Nasrallah, HA | 1 |
| Nasrallah, AT | 1 |
| Zdanys, K | 1 |
| Tampi, RR | 1 |
| Bressan, RA | 1 |
| Pilowsky, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
| Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia[NCT03860597] | Phase 4 | 42 participants (Actual) | Interventional | 2018-04-01 | Completed | ||
| Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial[NCT05944510] | Phase 4 | 72 participants (Anticipated) | Interventional | 2023-08-31 | Recruiting | ||
| Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia[NCT05803447] | 120 participants (Actual) | Observational | 2016-09-01 | Completed | |||
| A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?[NCT02234752] | Phase 2 | 3 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Funding no longer available and PI no longer working at the institution) | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study[NCT00757978] | Phase 4 | 22 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 ms, 85 dB clicks were presented in 500 ms trains at a frequency of 40 Hz; 250 click trains were played (inter-train interval=0.5 s). EEG was continuously recorded with 64-channel BioSemi ActiveTwo system (sampling rate=2048 Hz). Data processed offline via Matlab, EEGlab, & BrainVision Analyzer. Continuous data were segmented relative to stimulus onset (-100 ms to 500 ms) & each epoch was baseline-corrected relative to 100 ms pre-stimulus interval. γEP was assessed based on first 100 artifact-free epochs at Fz. Averaged epochs across click trains were transformed into power spectrum via fast Fourier transform using a bin width of 2 Hz. 40 Hz power spectrum was averaged across 4 Hz band from 38-42 Hz. Data were analyzed by RM-ANOVA, with diagnosis as a between- & drug condition (placebo vs MEM) as a within-subject factor. Analyses revealed robust & time bin-independent effects of diagnosis & drug across 200-500 ms window & thus this interval was the focus of all subsequent analyses. (NCT03860597)
Timeframe: 7 and 14 days post baseline
| Intervention | Microvolts-squared (Mean) | |
|---|---|---|
| Placebo | Memantine | |
| Healthy Subjects: 20 mg Memantine 1st, Then Placebo | 0.14 | 0.23 |
| Healthy Subjects: Placebo 1st, Then 20 mg Memantine | 0.14 | 0.23 |
| Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | 0.07 | 0.06 |
| Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | 0.08 | 0.09 |
85 dB SPL stimuli were presented via Etymotic ER3-A insert earphones. A 4-tone auditory oddball paradigm with 82% standards & 18% deviant stimuli, differed from standard in pitch, duration, or both. A pseudorandomized sequence produced a minimum of 3 standard tones between each deviant stimulus. All tones had 5-ms rise/fall times presented with a fixed 500-ms stimulus onset asynchrony. Subjects viewed a silent movie & instructed to ignore auditory stimuli. EEG were continuously recorded at a sampling rate of 2048-Hz from 64 channels, using BioSemi ActiveTwo system & downsampled to 512-Hz. Deviant-minus-standard difference waves were generated for each deviant type & low-pass filtered (20-Hz zerophase shift, 24 dB/octave rolloff). MMN was computed as mean amplitude across 135-205 ms range for each deviant type in difference waveforms at electrode Fz. Data were analyzed by RM-ANOVA, with diagnosis as a between-subject factor, & drug condition (placebo vs MEM) as a within-subject factor. (NCT03860597)
Timeframe: 7 and 14 days post baseline
| Intervention | microvolts (Mean) | |
|---|---|---|
| Placebo | Memantine | |
| Healthy Subjects: 20 mg Memantine 1st, Then Placebo | -3.52 | -3.28 |
| Healthy Subjects: Placebo 1st, Then 20 mg Memantine | -3.52 | -3.28 |
| Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | -1.60 | -1.70 |
| Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | -3.15 | -2.44 |
"PPI of the startle reflex is the automatic reduction in startle magnitude (assessed by EMG of orbicularis oculi) when a startling stimulus (40 ms 118 dB(A) noise burst; PULSE) is preceded (10-120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background PREPULSE). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal negative value of inhibition. There is no clear advantage or disadvantage for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects. Day 1 was baseline testing: testing occurred, data was collected, but no intervention was given. There were two possible interventions: active (MEM 20 mg po) and placebo. One intervention was given on day 7 post baseline, the other intervention was given on day 14 post baseline, with order of intervention balanced." (NCT03860597)
Timeframe: 7 and 14 days post baseline
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Memantine | |
| Healthy Subjects: 20 mg Memantine 1st, Then Placebo | 11.78 | 25.55 |
| Healthy Subjects: Placebo 1st, Then 20 mg Memantine | 14.11 | 21.36 |
| Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | 26.85 | 20.55 |
| Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | 32.45 | 10.11 |
The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | units on a scale (Number) | ||||
|---|---|---|---|---|---|
| Baseline Participant 1 | Week 6 Participant 1 | Baseline Participant 2 | Week 6 Participant 2 | Baseline Participant 3 | |
| Galantamine ER, Memantine XR | 48 | 48 | 32 | 25 | 9 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline tryptophan Participant 1 | Week-6 tryptophan Participant 1 | Baseline tryptophan Participant 2 | Week-6 tryptophan Participant 2 | Baseline tryptophan Participant 3 | |
| KP Metabolites Values | 51.94 | 55.72 | 32.17 | 24.96 | 35.07 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYN/TRP Participant 1 | Week-6 KYN/TRP Participant 1 | Baseline KYN/TRP Participant 2 | Week-6 KYN/TRP Participant 2 | Baseline KYN/TRP Participant 3 | |
| KP Metabolites Values | 1.21 | 1.31 | 1.06 | 0.8 | 0.79 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYNA/KYN Participant 1 | Week-6 KYNA/KYN Participant 1 | Baseline KYNA/KYN Participant 2 | Week-6 KYNA/KYN Participant 2 | Baseline KYNA/KYN Participant 3 | |
| KP Metabolites Values | 0.075 | 0.050 | 0.121 | 0.114 | 0.152 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYNA Participant 1 | Week-6 KYNA Participant 1 | Baseline KYNA Participant 2 | Week-6 KYNA Participant 2 | Baseline KYNA Participant 3 | |
| KP Metabolites Values | 103911 | 83737 | 95139 | 73280 | 93163 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYN Participant 1 | Week-6 KYN Participant 1 | Baseline KYN Participant 2 | Week-6 KYN Participant 2 | Baseline KYN Participant 3 | |
| KP Metabolites Values | 1.62 | 1.85 | 0.86 | 0.71 | 0.76 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline PIC/KYN Participant 1 | Week-6 PIC/KYN Participant 1 | Baseline PIC/KYN Participant 2 | Week-6 PIC/KYN Participant 2 | Baseline PIC/KYN Participant 3 | |
| KP Metabolites Values | 0.0317 | 0.0175 | 0.1039 | 0.0989 | 0.0655 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline PIC Participant 1 | Week-6 PIC Participant 1 | Baseline PIC Participant 2 | Week-6 PIC Participant 2 | Baseline PIC Participant 3 | |
| KP Metabolites Values | 44021 | 29542 | 81883 | 63745 | 40189 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
13 reviews available for memantine and Schizophrenia
| Article | Year |
|---|---|
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Memantine; Psychiatri | 2019 |
Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Topics: Animals; Antipsychotic Agents; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Memanti | 2020 |
Memantine in neurological disorders - schizophrenia and depression.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Clinical Trials as Topic; Depression | 2021 |
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Memantine; Psychiatric | 2018 |
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Topics: Auditory Perception; Cognitive Dysfunction; Excitatory Amino Acid Agonists; Excitatory Amino Acid An | 2018 |
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
Topics: Bipolar Disorder; Cognition; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials.
Topics: Antipsychotic Agents; Humans; Memantine; Randomized Controlled Trials as Topic; Receptors, N-Methyl- | 2013 |
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
Topics: Animals; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Memantine; Nootropic A | 2014 |
The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.
Topics: Clozapine; Drug Delivery Systems; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitat | 2014 |
[Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
Topics: Alzheimer Disease; Binding Sites; Brain Ischemia; Dizocilpine Maleate; Humans; Magnesium; Memantine; | 2004 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
Imaging the glutamatergic system in vivo--relevance to schizophrenia.
Topics: Brain Chemistry; Humans; Ketamine; Memantine; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Gl | 2000 |
16 trials available for memantine and Schizophrenia
| Article | Year |
|---|---|
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia.
Topics: Double-Blind Method; Electroencephalography; Excitatory Amino Acid Antagonists; Humans; Memantine; S | 2020 |
Memantine effects on auditory discrimination and training in schizophrenia patients.
Topics: Auditory Perception; Discrimination, Psychological; Double-Blind Method; Humans; Memantine; Receptor | 2020 |
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O | 2017 |
The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 2017 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Ky | 2018 |
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid A | 2013 |
Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Meth | 2016 |
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Drug Resistance; Drug Synergism; Drug | 2017 |
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2017 |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B | 2016 |
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excit | 2009 |
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Bli | 2009 |
Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Double-Blind Me | 2010 |
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Cognition Disorders; Female; Humans; Inpatients; | 2008 |
Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.
Topics: Adult; Antipsychotic Agents; Dominance, Cerebral; Dopamine Agents; Double-Blind Method; Drug Therapy | 2007 |
16 other studies available for memantine and Schizophrenia
| Article | Year |
|---|---|
Adjunct memantine for clozapine rechallenge following cardiomyopathy.
Topics: Antipsychotic Agents; Cardiomyopathies; Clozapine; Humans; Memantine; Schizophrenia | 2020 |
Antipsychotics-associated obsessive-compulsive symptoms: individualized treatments and clinical benefits of memantine: a case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Memantine; Obsessive-Compulsive Disorder; Schizophrenia; | 2020 |
Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Humans; Memantine; Risperidone; Schizop | 2017 |
Response to the letter from Dr. Veerman and colleagues.
Topics: Antipsychotic Agents; Cognition; Humans; Memantine; Schizophrenia | 2017 |
Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Cognition; Humans; Memantine; Schizophrenia | 2017 |
Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.
Topics: Animals; Antipsychotic Agents; Auditory Perception; Humans; Learning; Memantine; Neuronal Plasticity | 2018 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
Topics: Animals; Animals, Newborn; Auditory Cortex; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum | 2019 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.
Topics: Animals; Benzazepines; Brain; Carrier Proteins; Disks Large Homolog 4 Protein; Dopamine; Dopamine Ag | 2014 |
Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study.
Topics: Adult; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Psy | 2014 |
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituatio | 2016 |
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Biological Transport; Brain; B | 2011 |
Memantine as a neuroprotective treatment in schizophrenia.
Topics: Calcium; Glutamic Acid; Humans; Memantine; Neurons; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2005 |
[Memantine as an adjunctive therapy for schizophrenia negative symptoms].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Memantine; Middle Aged; Rece | 2005 |
Memantine-associated reversal of clozapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine Agents; Humans; Male; Memantine; N-Methylaspartate; | 2007 |